Histology-tailored multidisciplinary management of primary retroperitoneal sarcomas.
Chemotherapy
Diagnosis
Liposarcoma
Radiotherapy
Retroperitoneal sarcoma
Retroperitoneal tumour
Solitary fibrous Tumor
Surgery
leiomyosarcoma
Journal
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
ISSN: 1532-2157
Titre abrégé: Eur J Surg Oncol
Pays: England
ID NLM: 8504356
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
03
02
2022
revised:
02
05
2022
accepted:
11
05
2022
medline:
29
5
2023
pubmed:
23
5
2022
entrez:
22
5
2022
Statut:
ppublish
Résumé
Until recently, the recommendation for primary retroperitoneal sarcomas (RPS) was to perform a complete en-bloc gross excision, (neo) adjuvant treatments being options which were not validated by randomized studies, with a large discrepancy of use between centers. The heterogeneity of RPS, with their different biological behaviour, renders a homogenous therapeutic and surgical approach probably inappropriate. Recent studies, both surgical and dedicated to adjuvant treatments, allow refining these recommendations. This review summarizes recent advances and directions.
Identifiants
pubmed: 35599138
pii: S0748-7983(22)00435-8
doi: 10.1016/j.ejso.2022.05.010
pii:
doi:
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1061-1067Informations de copyright
Copyright © 2022 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors have no potential conflicts of interest to disclose.